Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Servier Offers $483 Million To Buy Rest Of Hungarian Generics Maker Egis

This article was originally published in The Pink Sheet Daily

Executive Summary

After holding a 51% stake in Egis for 18 years, France's mid-sized pharma company Servier is now offering nearly $483 million to buy the rest of the Hungarian generics company.

You may also be interested in...



Double-Jointed Partnership With Servier Could Jumpstart Amgen’s CV Portfolio

Amgen gets U.S. rights to a pair of heart failure candidates from the French firm, with the lead candidate already approved in Europe and likely to be filed quickly at FDA. Meanwhile, Servier obtains EU commercialization rights to a CV drug partnered between Amgen and Cytokinetics.

Korea's Celltrion Signs Deal with Hungary's Egis Pharmaceuticals to Sell Biosimilars In Former Soviet Republic Countries, Eastern Europe

SEOUL - South Korea's Celltrion has signed a deal with Hungary's Egis Pharmaceuticals to sell Celltrion's future biosimilar products in the former Soviet Republic countries and Eastern Union

Pipeline Watch: Phase III Readouts In Alopecia Areata, Cervical Dysplasia, Anaphylaxis

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Topics

Related Companies

UsernamePublicRestriction

Register

ID005817

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel